跳至主要内容
临床试验/NCT01892852
NCT01892852Unknown不适用

Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study

Pusan National University Hospital1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2013年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
36
试验地点
1
主要终点
Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline

研究概览

简要总结

The purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma.
  • •Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta and/or Lyrica. Patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period.
  • •Patients, or the legal guardians of patients, must have the ability to understand Korean, and be ble to provide informed consent.
  • •ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or
  • •If the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception.

排除标准

  • •Other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and HIV.
  • •Current active treatment for lymphoma or multiple myeloma
  • •Ongoing local infection at or near the acupuncture point adopted in this trial.
  • •Severe immunocompromised patients, leukopenia ( < 4,000/㎣) or neutropenia ( < 1,500/㎣)
  • •Known coagulopathy, thrombocytopenia (< 50,000/㎣), and taking heparin (including low molecular weight heparin) or Coumadin at any dose.
  • •Serious emotional or mental problems that precludes study entry.
  • •Mental and physical disability that precludes accurate acupuncture.
  • •Serious systemic diseases such as active infection, severe heart disease, uncontrolled hypertension and diabetes mellitus.
  • •Cardiac pacemaker.
  • •Pregnant or breastfeeding
  • •Acupuncture therapy within the previous 30 days
  • •Concurrent other complementary and alternative therapy such as herbal agents, high dose vitamins, and etc.

研究组 & 干预措施

Acupuncture

Experimental

Acupuncture treatment

干预措施: Acupuncture (Procedure)

Control

No Intervention

No other active treatment or sham acupuncture for this symptoms

结局指标

主要结局

Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline

时间窗: At baseline, 1, 2, 3, and 7 wks from baseline

次要结局

  • Change of VAS (Visual Analogue Scale) from baseline(At baseline, 1, 2, 3, and 7 wks from baseline)
  • Change of FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity) from baseline(At baseline, 1, 2, 3, and 7 wks from baseline)
  • Adverse events(From study enrollment to the last follow-up (up to 7 wks))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验